Cargando…

A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease

BACKGROUND AND AIMS: Lower-cost biosimilar infliximab may address affordability concerns in the treatment of adults with Crohn’s disease (CD), however, evidence regarding the cost-effectiveness of switching from reference to biosimilar is warranted. The aim of this research was to assess the increme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Avery, Marshall, John K, Moretti, Myla E, Ungar, Wendy J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898373/ https://www.ncbi.nlm.nih.gov/pubmed/33644677 http://dx.doi.org/10.1093/jcag/gwz045

Ejemplares similares

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
por: Bashir, Naazish S., et al.
Publicado: (2023)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla, Abuelmagd, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
por: Saleem, Ramsey, et al.
Publicado: (2020)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
por: Cohen, Stanley B., et al.
Publicado: (2018)

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
por: Alten, Rieke, et al.
Publicado: (2019)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_68jiefdqs3d9s364mtt5a497ka